Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 5/20 | 0.62 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.40 |
| ▸ | CSNK2A3 | Q8NEV1 | 2/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20782029 | 0.81 | ALOX5 (0.50) | CSNK2A1ESR1 | |
| SCHEMBL25765785 | 0.81 | ESR2 (0.50) | CSNK2A1CYP2A6ESR1MMP2MMP3 | |
| SCHEMBL19567203 | 0.81 | CSNK2A1 (0.64) | CSNK2A1CYP2A6CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL17859650 | 0.80 | CSNK2A1 (0.68) | CSNK2A1CYP2A6CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL11830040 | 0.79 | CSNK2A1 (0.50) | CSNK2A1PTGES2RORCMMP2MMP3 | |
| SCHEMBL3900981 | 0.78 | CSNK2A1 (0.70) | CSNK2A1CYP2A6CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL3912942 | 0.78 | CSNK2A1 (0.70) | CSNK2A1CYP2A6CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL12866824 | 0.78 | AOC3 (0.49) | CYP2A6MAOBHTR7 | |
| SCHEMBL20781813 | 0.77 | CYP1A1 (0.44) | CYP2A6MMP2MMP3HTR7 | |
| SCHEMBL27992345 | 0.77 | CSNK2A1 (0.58) | CSNK2A1HSD11B1PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210179564-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-20190071404-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071404-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | CSNK2A1 87/4885CYP2A6 3670/4885PTGES2 518/4885 |
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | CSNK2A1 87/4885CYP2A6 3670/4885PTGES2 518/4885 |
| US-20210179564-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | CSNK2A1 87/4885CYP2A6 3670/4885PTGES2 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.